Remote patient monitoring
Remote Patient Monitoring (RPM) effectively captures patient-generated data at regular intervals using digital biomarkers and electronic Patient-Reported Outcome (ePROs).
Combining these data points with electronic Clinical Outcome Assessment (eCOA), Aparito provides a comprehensive profile of patients for clinical research and trials via Atom5™ without increasing patient burden.
RPM and real-world evidence
RPM enables the collection of real-world evidence (RWE) via the Atom5™ app and wearable devices without your patients leaving home and combines passive data from sleep and vitals with active data via ePROs and eCOAs. A key benefit of RPM is to increase the quality of life of patients by reducing visits to clinical sites and hospitalisations.
RPM uses remote or wearable patient monitoring devices that measure or detect common physiological parameters and then transmit electronically patient information to the monitoring entity.
During the initial COVID-19 outbreak in early 2020, oncology patients were monitored via Aparito’s Atom5TM platform, allowing them to continue their treatment or their ongoing participation in clinical trials while keeping them and the clinical trials team safe. The use of RPM was seen as an improvement to monitor and manage cancer patients in terms of clinical work and patients’ quality of life and minimse the risk to immunocomprised patients posed by the novel coronavirus.
Aparito and Remote Patient Monitoring
By remotely collecting meaningful, relevant, and real-time data and analysing patient-generated data, Atom5™ enables a centralised view to support diagnosis, treatment and drug development.